CYP19A1 and breast cancer: An ongoing phase II randomised clinical trial (NCT01589367) aims to investigate the effect of the aromatase inhibitor letrozole with metformin in postmenopausal patients with ER + BC.143 Further such studies are required in order to formulate guidelines to advise clinicians on the possible therapeutic implementation of metformin in BC.